Navigation Links
SPO Medical Granted Innovative Baby Monitoring Patent

NEW YORK, February 18, 2010 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, today announced it has been granted a new and innovative baby monitoring patent relating to a non-invasive device or system for monitoring and measuring the heart rate of a baby to activate an alarm when the level falls outside a predetermined range. This issuance by the United States Patent and Trademark Office (Patent # 7,650,176) brings the Company's intellectual property (IP) portfolio to a total of twelve patents. This latest patent, developed by the SPO Medical engineering team, increases the Company's technological competitive edge in providing an innovative, high performance solution for a market application applicable to most family homes.

This new patent focuses on commercial applications relating to the implementation of reflectance pulse oximetry for monitoring babies and infants particularly for ages up to 12 months. During their first year, babies have increased susceptibility to breathing disturbances and respiratory ailments which could lead to physiological distress. Early detection of a respiratory ailment could provide the time to administer aid necessary to prevent further deterioration of a baby's wellness. Many types of consumer baby monitors are currently available but most do not give the advance warning necessary for the caregivers to administer aid. In addition, certain baby movement monitors are known to have a high level of "false alarms" as they have no way to distinguish between the lapses in breathing, which can be normal for a baby, and respiratory distress. This could result in increased anxiety for the caregivers or cause them to ignore a signal after responding repeatedly to false alarms. The new patent granted to SPO specifically addresses this concern by providing a pro-active solution through a real-time baby monitoring application.

Michael Braunold, President and Chief Executive Officer of SPO Medical commented: "The granting of this innovative patent could have a major impact on the baby monitoring market - it enables the commercialization of a pro-active monitoring device that can help safeguard a baby during those first-year critical months especially when parental or caregiver anxiety is potentially high. With over 8 million births annually in the USA and Western Europe alone, our objective is to make available this unique technology to client corporations who have an interest in commercializing and distributing a product which delivers parental reassurance attributes with real-time monitoring of babies particularly while they are sleeping."

The Company has established a dedicated web site relating to this homecare application; it can be viewed at along with a video demonstration of the proposed commercial unit and a facility for making additional enquires to the Company into this innovative product opportunity.

About SPO Medical:

SPO Medical (OTC: SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit and

Forward Looking Statements:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, patent protection for our products and technologies, market acceptance of our products and new product applications, product performance, size of prospective markets, revenues assessments, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the sufficiency and availability of working capital, the introduction of competing products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2008. We undertake no obligation to revise or update any forward-looking statement for any reason.

SPO Medical Contact: Michael Braunold, Chief Executive Officer,, +1-866-991-7766

SOURCE SPO Medical Inc.

SOURCE SPO Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
(Date:11/26/2015)... Un nuevo enfoque combina la ... cáncer avanzado.   --> Un nuevo ... Bremachlorin para el cáncer avanzado.   --> ... la terapia fotodinámica de Bremachlorin para el cáncer avanzado. ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 26, 2015 ... aanpak combineert immunotherapie met Bremachlorin-photodynamische therapie voor ... ) --> ... ) Uit ... Centrum (LUMC) blijkt ...
(Date:11/26/2015)... FRANCISCO , November 26, 2015 ... billion by 2022, according to a new report by Grand ... Chronic Kidney Disease (CKD) which demands kidney transplantation is expected ... and cost effective substitute for organ transplantation. --> ... billion by 2022, according to a new report by Grand ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, announces ... This is one of Joplin's most famous and beautiful concert posters. The concert was ... in Ann Arbor. The According to Hawley, "It is hard to believe that Joplin's ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... 26, 2015 , ... The Catalent Applied Drug Delivery Institute ... integrate dose form selection in early phase drug development. The first of these ... bringing together the UK’s emerging life sciences companies, corporate partners, and investors, at ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... second medical opinion process, participated in the 61st annual Employee Benefits Conference. The ... and took place Sunday, November 8th through Wednesday, November 11th, 2015. The conference ...
(Date:11/26/2015)... ... 26, 2015 , ... Indosoft Inc., developer and distributor of the world-class Asterisk ... system efficiency and reliability. , The new Q-Suite 6 platform is based on the ... locking itself into a specific piece of software for many key components of the ...
Breaking Medicine News(10 mins):